Intermediate Risk Prostate Cancer May Be Safely Controlled with Brachytherapy Alone

Intermediate Risk Prostate Cancer May Be Safely Controlled with Brachytherapy Alone
Patients with prostate cancer who receive brachytherapy alone have similar cancer control rates and fewer side effects compared to those who receive brachytherapy in combination with external beam therapy (EBT), according to the results of a Phase 3 clinical trial. The abstract, "Initial Report of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma Identification and Validation of Intrinsic Subtypes of Prostate Cancer," was recently presented at the American Society for Radiation Oncology 2016 Annual Meeting, held September 25-18, in Boston. The two main types of radiation therapy used for prostate cancer are external beam radiation, which is noninvasive, and brachytherapy, in which radioactive seed implants are placed directly inside the prostate, reducing radiation exposure to healthy tissues. To address whether adding EBT to brachytherapy improved the outcomes of prostate cancer patients compared to brachytherapy alone, the researchers conducted the NRG Oncology/RTOG 0232 randomized, multi-institutional Phase 3 study (NCT00063882), which included patients with intermediate risk prostate cancer. Risk groups were defined based on Gleason scores - which reveal how aggressive a tumor is - and PSA blood levels at the time of diagnosis. Eligible patients for this study had either a Gleason score between two and s
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *